Recruiting Multiple Myeloma Studies in Prague
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researche...
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP...
About Multiple Myeloma Clinical Trials in Prague
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 2 multiple myeloma clinical trials recruiting participants in Prague, PRAGUE. These studies are seeking a combined 90 participants. Research is being sponsored by Glycomine, Inc., Kedrion S.p.A.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Prague — FAQ
Are there multiple myeloma clinical trials in Prague?
Yes, there are 2 multiple myeloma clinical trials currently recruiting in Prague, PRAGUE. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Prague?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Prague research site will contact you about next steps.
Are clinical trials in Prague free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Prague studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 2 active trials in Prague are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov